Colorectal Cancer Clinical Trial
— CRC-NORDIETOfficial title:
The Norwegian Dietary Guidelines and Colorectal Cancer Survival Study
Verified date | March 2022 |
Source | University of Oslo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current study is designed to gain a better understanding of the role of a healthy diet aimed at dampening inflammation and oxidative stress on long-term disease outcomes and survival in colorectal cancer patients. Since previous research on the role of diet for colorectal cancer survivors is limited, the study may be of great importance for this cancer population.
Status | Active, not recruiting |
Enrollment | 503 |
Est. completion date | December 31, 2040 |
Est. primary completion date | December 31, 2034 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: - colorectal cancer (ICD10 C18-20) TNM Stage I-III Exclusion Criteria: - TNM stage 0 or IV |
Country | Name | City | State |
---|---|---|---|
Norway | Akershus University Hospital | Lørenskog | |
Norway | Oslo University Hospital | Oslo | |
Norway | University of Oslo | Oslo |
Lead Sponsor | Collaborator |
---|---|
University of Oslo | Finnish Institute for Health and Welfare, Norwegian Cancer Society, Oslo University Hospital, The Research Council of Norway, University Hospital, Akershus |
Norway,
Alavi DH, Henriksen HB, Lauritzen PM, Kværner AS, Sakinis T, Langleite TM, Henriksen C, Bøhn SK, Paur I, Wiedswang G, Smeland S, Blomhoff R. Quantification of adipose tissues by Dual-Energy X-Ray Absorptiometry and Computed Tomography in colorectal cancer — View Citation
Henriksen C, Paur I, Pedersen A, Kværner AS, Ræder H, Henriksen HB, Bøhn SK, Wiedswang G, Blomhoff R. Agreement between GLIM and PG-SGA for diagnosis of malnutrition depends on the screening tool used in GLIM. Clin Nutr. 2022 Feb;41(2):329-336. doi: 10.10 — View Citation
Henriksen HB, Berntsen S, Paur I, Zucknick M, Skjetne AJ, Bøhn SK, Henriksen C, Smeland S, Carlsen MH, Blomhoff R. Validation of two short questionnaires assessing physical activity in colorectal cancer patients. BMC Sports Sci Med Rehabil. 2018 May 29;10 — View Citation
Henriksen HB, Carlsen MH, Paur I, Berntsen S, Bøhn SK, Skjetne AJ, Kværner AS, Henriksen C, Andersen LF, Smeland S, Blomhoff R. Relative validity of a short food frequency questionnaire assessing adherence to the Norwegian dietary guidelines among colorec — View Citation
Henriksen HB, Ræder H, Bøhn SK, Paur I, Kværner AS, Billington SÅ, Eriksen MT, Wiedsvang G, Erlund I, Færden A, Veierød MB, Zucknick M, Smeland S, Blomhoff R. The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-base — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free survival | Disease-free survival (DFS) (events are defined as detection of local recurrence or metastasis or any second cancer or death from any cause) | 5, 10 and 15 years | |
Primary | Overall survival | Overall survival (OS) (event is defined as death from any cause) | 10, 15 years | |
Secondary | Time to recurrence | Events are defined as detection of local recurrence or metastasis | up to 15 years | |
Secondary | CVD -free survival | Events of CVD (ICD-10; chapter I) or death from any cause | up to 15 years | |
Secondary | CRC-specific survival | death due to CRC | up to 15 years | |
Secondary | Total cancer-specific survival | death due to CRC or any other cancer | up to 15 years | |
Secondary | Inflammatory disease-specific survival | death due to inflammatory disease | up to 15 years | |
Secondary | Cardiovascular (CVD)-specific survival | death due to CVD | up to 15 years | |
Secondary | New morbidity of other diet-related chronic diseases | e.g. ischemic coronary heart disease, cerebrovascular disease, thromboembolic disease, type 2 diabetes, obesity, hypertension and chronic obstructive pulmonary disease | up to 15 years | |
Secondary | Dietary intake and nutritional status | Questionnaires, food records, clinical consultation | up to 15 years | |
Secondary | Physical activity and function | Questionnaires, arm band, physical tests | up to 15 years | |
Secondary | Nutrition biomarkers | e.g., carotenoids, fatty acids, 25-hydroxy vitamin D etc | up to 15 years | |
Secondary | Body composition | DXA, CT, BIA | up to 15 years | |
Secondary | Anthropometric measures | eg weight, waist and hip circumference | up to 15 years | |
Secondary | Biomarkers for inflammation and oxidative stress | e.g. isoprostanes, cytokines | up to 15 years | |
Secondary | Transcription- and epigenetic profiles | sequencing and arrays | up to 15 years | |
Secondary | Biomarkers for cardiovascular disease, metabolic syndrome, type 2-diabetes, thromboembolic disease and cancer | e.g. blood pressure, total/LDLcholesterol, HbA1c, CRP, IL-6, IL-10, TNFa | up to 15 years | |
Secondary | Health related quality of life and fatigue | Questionnaires | up to 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |